The Potential Cardiovascular Benefits of COVID-19 Vaccination: Lessons from Influenza and Emerging Evidence
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 8, 2023 Category: Cardiology Source Type: research
A Multimodal Omics Framework to Empower Target Discovery for Cardiovascular Regeneration
AbstractIschaemic heart disease is a global healthcare challenge with high morbidity and mortality. Early revascularisation in acute myocardial infarction has improved survival; however, limited regenerative capacity and microvascular dysfunction often lead to impaired function and the development of heart failure. New mechanistic insights are required to identify robust targets for the development of novel strategies to promote regeneration. Single-cell RNA sequencing (scRNA-seq) has enabled profiling and analysis of the transcriptomes of individual cells at high resolution. Applications of scRNA-seq have generated single...
Source: Cardiovascular Drugs and Therapy - July 8, 2023 Category: Cardiology Source Type: research
The Potential Cardiovascular Benefits of COVID-19 Vaccination: Lessons from Influenza and Emerging Evidence
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 8, 2023 Category: Cardiology Source Type: research
Dexmedetomidine Alleviates Abdominal Aortic Aneurysm by Activating Autophagy Via AMPK/mTOR Pathway
ConclusionDEX ameliorates AAA in rat models by activating autophagy via the AMPK/mTOR pathway. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 1, 2023 Category: Cardiology Source Type: research
The Role of P53 in Myocardial Ischemia-Reperfusion Injury
AbstractPurposeP53 is one of the key tumor suppressors. In normal cells, p53 is maintained at low levels by the ubiquitination of the ubiquitinated ligase MDM2. In contrast, under stress conditions such as DNA damage and ischemia, the interaction between p53 and MDM2 is blocked and activated by phosphorylation and acetylation, thereby mediating the trans-activation of p53 through its target genes to regulate a variety of cellular responses. Previous studies have shown that the expression of p53 is negligible in normal myocardium, tends to increase in myocardial ischemia and is maximally induced in ischemia-reperfused myoca...
Source: Cardiovascular Drugs and Therapy - June 30, 2023 Category: Cardiology Source Type: research
Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
ConclusionsLira therapy protects against AngII-mediated diastolic dysfunction, at least in part by promoting amino acid uptake and protein turnover in the heart. Liraglutide therapy is associated with loss of mean muscle mass, and long-term studies are warranted to investigate sarcopenia and frailty with liraglutide therapy in the setting of diastolic disease. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 29, 2023 Category: Cardiology Source Type: research
Sacubitril/Valsartan in Dialysis Patients: Update on Current Perspectives
AbstractSacubitril/Valsartan is a combination of neprilysin inhibitor and angiotensin II receptor blocker that proved its own efficacy and safety in heart failure patients to ameliorate cardiovascular morbidity and mortality compared to angiotensin II-converting enzyme inhibitors alone. However, end-stage renal disease patients have not been included in the randomized controlled trials, so the beneficial effects as well as the risk profile of this association remain still undefined in these patients. Only observational studies on this drug association have been carried out in end-stage renal disease patients investigating ...
Source: Cardiovascular Drugs and Therapy - June 22, 2023 Category: Cardiology Source Type: research
Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes
AbstractHeart failure with preserved ejection fraction (HFpEF) is now the most common form of heart failure (HF). This syndrome is associated with an elevated morbi-mortality, and effective therapies are urgently needed. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the first pharmacological class that has demonstrated to reduce hospitalization and cardiovascular mortality in large clinical trials in HFpEF. Furthermore, the dual SGLT 1/2 inhibitor sotagliflozin has shown a reduction in cardiovascular outcomes in diabetic HF patients, regardless of ejection fraction Sotagliflozin on Cardiovascular Events in Patien...
Source: Cardiovascular Drugs and Therapy - June 15, 2023 Category: Cardiology Source Type: research
Rivaroxaban Combined with Atorvastatin Inhibits Acute Pulmonary Embolism by Promoting the Expression of NRF2/NQO1
ConclusionThe alleviating effect of rivaroxaban + atorvastatin administration against APE correlates with NRF2/NQO1 expression. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 15, 2023 Category: Cardiology Source Type: research
Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes
AbstractHeart failure with preserved ejection fraction (HFpEF) is now the most common form of heart failure (HF). This syndrome is associated with an elevated morbi-mortality, and effective therapies are urgently needed. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the first pharmacological class that has demonstrated to reduce hospitalization and cardiovascular mortality in large clinical trials in HFpEF. Furthermore, the dual SGLT 1/2 inhibitor sotagliflozin has shown a reduction in cardiovascular outcomes in diabetic HF patients, regardless of ejection fraction Sotagliflozin on Cardiovascular Events in Patien...
Source: Cardiovascular Drugs and Therapy - June 15, 2023 Category: Cardiology Source Type: research
Rivaroxaban Combined with Atorvastatin Inhibits Acute Pulmonary Embolism by Promoting the Expression of NRF2/NQO1
ConclusionThe alleviating effect of rivaroxaban + atorvastatin administration against APE correlates with NRF2/NQO1 expression. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 15, 2023 Category: Cardiology Source Type: research
